Histogenics Corporation (HSGX), a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace.
HSGX offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
HSGX has an exclusive channel collaboration agreement with Intrexon Corporation (XON) for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.
Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
January 3, 2020
RegMed Investors’ (RMi) closing bell: volatility sets the tone for first two trading sessions post a holiday
January 2, 2020
RegMed Investors’ (RMi) closing bell: starting the year with another downside rotation from Tuesday’s close
December 31, 2019
RegMed Investors’ (RMi) closing bell: It’s over, 2019 ends with sadness and some glee
December 30, 2019
RegMed Investors’ (RMi) closing bell: a ringside seat to share price destruction
December 27, 2019
RegMed Investors’ (RMi) closing bell: another slippery slope and sliding sector as risk defines the investment pattern
December 26, 2019
RegMed Investors’ (RMi) closing bell: the sector tripped after all the good cheer
December 24, 2019
RegMed Investors’ (RMi) closing bell: a complacent session for indexes
December 23, 2019
RegMed Investors’ (RMi) closing bell: the upside needle moved after a quadruple witching Friday and collaboration transactions
December 20, 2019
RegMed Investors’ (RMi) closing bell:the sector closed down after Thursday’s spurt
December 19, 2019
RegMed Investors’ (RMi) closing bell: the sector jumped after two down sessions
35 companies, 1 interpreter!
Insight, foresight and recommendation
Histogenics (HSGX) -- Opened 2018 at $2.07, saw some ups at $2.92; opened February at $2.79 falling with a low of $2.50 to close 2/18 at $2.63.HSGX closed (1/25) its registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions with a solid book-running manager Canaccord Genuity. Another favorite ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors